- Home
- ICG vs TLSA Comparison
ICG vs TLSA Comparison
Compare ICG & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- TLSA
- Stock Information
- Founded
- ICG 2017
- TLSA 2013
- Country
- ICG China
- TLSA United Kingdom
- Employees
- ICG N/A
- TLSA N/A
- Industry
- ICG Semiconductors
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ICG Technology
- TLSA Health Care
- Exchange
- ICG Nasdaq
- TLSA Nasdaq
- Market Cap
- ICG 172.7M
- TLSA 187.0M
- IPO Year
- ICG 2023
- TLSA 2000
- Fundamental
- Price
- ICG $2.74
- TLSA $2.38
- Analyst Decision
- ICG Strong Buy
- TLSA
- Analyst Count
- ICG 2
- TLSA 0
- Target Price
- ICG $9.25
- TLSA N/A
- AVG Volume (30 Days)
- ICG 265.9K
- TLSA 382.9K
- Earning Date
- ICG 08-14-2025
- TLSA 08-12-2025
- Dividend Yield
- ICG N/A
- TLSA N/A
- EPS Growth
- ICG N/A
- TLSA N/A
- EPS
- ICG 0.07
- TLSA N/A
- Revenue
- ICG $53,729,346.00
- TLSA N/A
- Revenue This Year
- ICG N/A
- TLSA N/A
- Revenue Next Year
- ICG $747.16
- TLSA N/A
- P/E Ratio
- ICG $36.66
- TLSA N/A
- Revenue Growth
- ICG 384.54
- TLSA N/A
- 52 Week Low
- ICG $1.19
- TLSA $0.63
- 52 Week High
- ICG $12.04
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- ICG 54.14
- TLSA 77.08
- Support Level
- ICG $2.72
- TLSA $1.62
- Resistance Level
- ICG $2.90
- TLSA $1.89
- Average True Range (ATR)
- ICG 0.25
- TLSA 0.18
- MACD
- ICG -0.04
- TLSA 0.09
- Stochastic Oscillator
- ICG 30.28
- TLSA 81.20
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.